Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 6 von 334
Pharmacotherapy, 2008-08, Vol.28 (8), p.1033-1040
2008
Volltextzugriff (PDF)

Details

Autor(en) / Beteiligte
Titel
Extended- and Continuous-Cycle Oral Contraceptives
Ist Teil von
  • Pharmacotherapy, 2008-08, Vol.28 (8), p.1033-1040
Ort / Verlag
Oxford, UK: Blackwell Publishing Ltd
Erscheinungsjahr
2008
Quelle
MEDLINE
Beschreibungen/Notizen
  • Five new oral contraceptives, classified as extended‐ or continuous‐cycle oral contraceptives, have been approved by the United States Food and Drug Administration. These agents have various combinations of estrogen and progestin, and different effects on the length of women's menstrual cycles. Usually they shorten the duration of menses, decrease the frequency of menses to 4 times/year, or completely eliminate menses. These new oral contraceptives are given in the following regimens: 24 days followed by placebo for 4 days (24/4), 84 days followed by placebo for 7 days (84/7), or continuously (without placebo). These agents contain ethinyl estradiol 20 μg‐drospirenone 3 mg (24/4); ethinyl estradiol 20 μg‐norethindrone 1 mg (24/4); ethinyl estradiol 30 μg‐levonorgestrel 150 μg (84/7); ethinyl estradiol 30 μg‐levonorgestrel 150 μg (84/7) with very low‐dose ethinyl estradiol (10 μg/day) for 7 days; and ethinyl estradiol 20 μg‐levonorgestrel 90 μg continuously. Clinical trials have demonstrated that extended‐ and continuous‐cycle oral contraceptives are as effective in preventing pregnancy as traditional oral contraceptives. These new agents also have similar adverse effects; however, the only significantly different adverse effect compared with traditional oral contraceptives in clinical trials was change in bleeding pattern. These oral contraceptives are associated with more breakthrough bleeding and spotting than the traditional pills. Long‐term effects on efficacy and safety are not known, as these new products generally have been used for only 1–2 years. Extended‐ and continuous‐cycle oral contraceptives are a new option for women desiring decreased menses or for whom decreased menses may alleviate symptoms of coexisting medical conditions.

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX